S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral
November 10, 2016 8:04 AM ESTRodman & Renshaw downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral with a price target of $23.00 (from $81.00). The change follows its Q3 revenue and earnings miss.
Analyst Raghuram Selvaraju said, "In its financial results for 3Q16 reported earlier this week, Valeant reported adjusted... More
Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook Negative
November 8, 2016 2:14 PM ESTMoody's Investors Service downgraded the ratings of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and subsidiaries, including the Corporate Family Rating to B3 from B2 and the Probability of Default Rating to B3-PD from B2-PD. Other downgrades include the senior secured bank credit facilities to Ba3 (LGD 2) from Ba2 (LGD 2) and senior unsecured debt to Caa1 (LGD 5) from B3 (LGD 5). At the same time, Moody's affirmed Valeant's SGL-3 Speculative Grade Liquidity Rating. The rating outlook is negative.
The downgrade reflects Valeant's challenges in turning around its specialty pharmaceuticals business, resulting in weak... More
